Advertisement


Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

2016 ASCO Annual Meeting

Advertisement

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Gideon Michael Blumenthal, MD, of the US Food and Drug Administration, discuss milestone analyses with immune checkpoint inhibitors, targeted therapy, and standard therapy in metastatic non–small cell lung cancer trials submitted to the FDA (Abstract 9010).



Related Videos

Lymphoma

James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma

James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).

Global Cancer Care

Rakesh Chopra, MD, and Mary Gospodarowicz, MD, on The Indian Perspective of the Current State of Cancer Research and Treatment

Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.

Daniel F. Hayes, MD, ASCO President 2016–2017, on His Goals for the Coming Year

Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.

Gynecologic Cancers

Eric Roeland, MD, and Linda Van Le, MD, on Gynecologic Cancers: Managing Menopausal Symptoms in Survivors

Eric Roeland, MD, of the University of California, San Diego, and Linda Van Le, MD, of the University of North Carolina discuss ways to manage symptoms that affect up to 80% of postmenopausal women, diminishing their quality of life.

Colorectal Cancer

Alan P. Venook, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Analysis of CALGB-SWOG 80405

Alan Venook, MD, of the University of California, San Francisco, and John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, discuss the impact of primary tumor location on overall survival and progression-free survival in patients with advanced disease (Abstract 3504).

Advertisement

Advertisement




Advertisement